NICE wants more data on cancer drug Iressa
January 29th, 2010
Britain’s healthcare cost-effectiveness watchdog said it needed more data before deciding whether AstraZeneca Plc’s cancer drug Iressa can be offered on the state-run National Health Service.
The National Institute for Health and Clinical Excellence (NICE) said on Friday it wanted more information about Iressa’s effectiveness in increasing the time certain lung cancer patients survive without their disease worsening, and in increasing overall survival.